论文部分内容阅读
作者采用随机试验的方法对比了 Cefi-xime 和头孢三嗪治疗无并发症淋病奈瑟氏淋球菌尿道炎或宫颈炎的疗效及安全性。225例淋病患者(男75例,女150例),其中187例培养发现淋病奈瑟氏球菌生长。患者随机分为3组:第1组一次肌注头孢三嗪250mg,第2组一次口服 Cefixime 400mg 和第3组一次口服 Cefixime800mg。155例(男59例,女96例)定期进行了奈瑟氏球菌培养,并观察了药物的疗效及副作用。结果发现,108例以 Cefixime 治疗者治愈率为97%,47
The authors compared the efficacy and safety of Cefi-xime and ceftriaxone for the treatment of Neisseria gonorrhoeae urethritis or cervicitis without complications by randomized trials. 225 cases of gonorrhea patients (75 males and 150 females), of which 187 cases of Neisseria gonorrhoeae growth was found. Patients were randomly divided into three groups: group 1 intramuscular ceftriaxone 250mg, group 2 once oral Cefixime 400mg and group 3 once oral Cefixime 800mg. 155 cases (male 59 cases, female 96 cases) were regularly Neisseria culture, and observed the efficacy and side effects of the drug. The results showed that 108 cases of treatment with Cefixime cure rate of 97%, 47